GSK to pay $20M to SEC to resolve bribery charges
U.K. pharmaceutical giant GlaxoSmithKline will pay a civil money penalty in the amount of $20 million to the Securities and Exchange Commission to resolve charges concerning bribery payments made to government officials in China. Jaclyn Jaeger reports.
Related articles
-
News BriefDOJ secures $118 million penalty in FCPA violation case tied to Guatemalan telecom firm
The parent company of a telecom subsidiary in Guatemala agreed to pay $118.2 million to settle allegations of improper payments made to government officials, but the U.S. Department of Justice chose not to impose a compliance monitor to administer the firm’s compliance with the Foriegn Corrupt Practices Act (FCPA).
-
PremiumA case-by-case analysis of FCPA investigation closures
Foreign corruption enforcement relating to national security matters has been a common theme under the Trump administration. A second common theme continues to be the discrete way in which the DOJ has ended several FCPA investigations.
-
ArticleDOJ dismisses indictment against Cassava advisor amid legal flaws
The DOJ dropped a June 2024 indictment against a Cassava Sciences advisor, closing a case tied to an alleged short-selling scheme and related government probes. The case was criticized for fundamental flaws in evidence and legal procedures.